Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTTP | P55157 | 2/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 2/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | GFER | P55789 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | KLRK1 | P26718 | 1/20 | 0.35 |
| ▸ | MICA | Q29983 | 1/20 | 0.35 |
| ▸ | RAET1L | Q5VY80 | 1/20 | 0.35 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.34 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15836877 | 0.99 | MTTP (0.39) | MTTPPIK3CDALDH1A1EPHX2F10 | |
| SCHEMBL15816870 | 0.80 | CDK19 (0.59) | — | |
| SCHEMBL14662553 | 0.80 | CDK19 (0.59) | — | |
| SCHEMBL14662387 | 0.80 | CDK19 (0.58) | — | |
| SCHEMBL15816274 | 0.80 | CDK19 (0.58) | — | |
| SCHEMBL14670519 | 0.78 | ELANE (0.46) | ALDH1A1KMT2AKDM4ENPSR1 | |
| SCHEMBL14670570 | 0.77 | TSHR (0.43) | ALDH1A1KMT2AHPGDCNR1CNR2 | |
| SCHEMBL14670520 | 0.77 | ACLY (0.43) | KMT2ANPSR1CNR2KLRK1MICA | |
| SCHEMBL15815907 | 0.77 | JAK2 (0.50) | — | |
| SCHEMBL15815908 | 0.77 | JAK2 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140179664-A1 | Heterocyclyl Pyrimidine Analogues As JAK Inhibitors | CELLZOME LIMITED (GB) | 2014-06-26 | — | — | US | disclosed |
| US-20140179664-A1 | Heterocyclyl Pyrimidine Analogues As JAK Inhibitors | CELLZOME LIMITED (GB) | 2014-06-26 | — | — | US | disclosed |
| WO-2013014162-A1 | HETEROCYCLYL PYRIMIDINE ANALOGUES AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2013-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179664-A1 | Heterocyclyl Pyrimidine Analogues As JAK Inhibitors | JAK1, JAK3, JAK2 | MTTP 4770/4885PIK3CD 1053/4885ALDH1A1 3464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.